

## UNITED STATES DEPARTMENT OF COMMERCE Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS Weshington, D.C. 20231

SERIAL NUMBER FILING DATE FIRST NAMED INVENTOR ATTORNEY DOCKET NO. WALLACH-4 12/13/90 WALLACH 07/625,668 EXAMINER CARLSON, K 18M1 ROGER L. BROWDY PAPER NUMBER ART UNIT BROWDY & NEIMARK 419 SEVENTH STREET, NW 1812 WASHINGTON, DC 20004 DATE MAILED: This is a communication from the examiner in charge of your application. COMMISSIONER OF PATENTS AND TRADEMARKS

Ø	This a	application has been examined	Responsive to comm	unication filed	on 12-27-93 (#/C	This action is made final.	
A sh Faile	orten ure to	ed statutory period for response to respond within the period for respo	this action is set to expire	3.	month(s),	_ days from the date of this letter	
Part	1	THE FOLLOWING ATTACHMENT	(S) ARE PART OF THIS ACT	TION:		,	
3		Notice of References Cited by Examiner, PTO-892.  Notice of Art Cited by Applicant, PTO-1449.  Information on How to Effect Drawing Changes, PTO-1474.  Notice of Information Patent Application, Form PTO-152.					
Part	a	SUMMARY OF ACTION					
1	. 🛚	Claims 1-6, 8,9			·	are pending in the application.	
		Of the above, claims			<del> </del>	are withdrawn from consideration.	
2	. 囚	Claims 7			······································	have been cancelled.	
3	. 🗆	Claims				are allowed.	
4	. Æ	Claims 1-6, 8, 9				are rejected.	
5	. 🗆	Claims	<del></del>			are objected to.	
6.		Claims					
7.	-	This application has been filed with informal drawings under 37 C.F.R. 1.85 which are acceptable for examination purposes.					
8.	. 🗆	Formal drawings are required in re	sponse to this Office action.				
9.		The corrected or substitute drawings have been received on Under 37 C.F.R. 1.84 these drawings are acceptable not acceptable (see explanation or Notice re Patent Drawing; PTO-948).					
10.		The proposed additional or substitute sheet(s) of drawings, filed on has (have) been approved by the examiner.    disapproved by the examiner (see explanation):					
11.		The proposed drawing correction, filed on, has been _ approved disapproved (see explanation).					
12.		Acknowledgment is made of the claim for priority under U.S.C. 119. The certified copy has Deen received not been received					
		been filed in parent application	, serial no.	; fi	led on		
.13,	<u> </u>	Since this application appears to be in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11; 453 O.G. 213.					
14.		Other	•				

EXAMINER'S ACTION

5

10

15

20

This Office Action is in response to Paper #16, filed

December 22, 1992. Claims 1-6, 8, and 9 are pending and Claim 7 has been canceled.

Applicants argue that the priority of the instant application should not be set to the filing date of Israel Patent 095064 of July 12, 1990 but to September 12, 1988 which is the filing date of the US parent application to this instant application, 07/243092. Applicants proceed to point out where in '092 they believe that the instant invention is enabled. Examiner disagrees because '092 does not teach the protein sequence encoding TBP-1, the corresponding DNA sequence, nor demonstrate successful transfection of host cells for the expression of TBP-1. Indeed, only a portion of the N-terminal sequence of TBP-1 is known at the time of the filing of '092. Though '092 does offer guidance concerning how to make TBP-1 or the DNA encoding TBP-1, it does not teach how to use these protocols successfully in not one instance. This is the mandate of enablement under 35 USC 112, that is, the specification must teach how to make and use the invention claimed. predictable that TBP-1 would be encoded by a single gene, that is, it could be encoded by the gene that encodes the mature

5

10

protein. Therein the cDNA needed to transfect host cells would not be readily pulled from a Southern, for example. It would require undue experimentation to successfully determine from an N-terminal sequence the entire protein sequence encoding TBP-1, the isolated genomic DNA or cDNA, and if such DNA could be inserted into any expression system and expressed in any cell line such that a functional TBP-1 is recombinantly produced. Therein, the Examiner regretfully disagrees with the Applicants arguments that the invention as presently claimed is enabled in the parent application and maintains that the priority date be set to July 12, 1990.

The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.

The rejection of Claims 1-9 under 35 USC 112, first paragraph, is withdrawn.

The rejection of Claims 1-9 under 35 USC 112, second paragraph, is withdrawn.

The Applicants have made no arguments of the teachings of the references cited in the previous Office Action because of the date of priority issues discussed above. Therein, all rejections are maintained as follows:

5

Claims 1, 2, and 6-8 are rejected under 35 U.S.C. § 102(a) as being anticipated by Loetscher et al. or Schall et al. as discussed in the previous Office Action.

10

Claims 3 and 4 are rejected under 35 U.S.C. § 103 as being unpatentable over Loetscher et al. or Schall et al. in view of Sambrook et al. as discussed in the previous Office Action.

15

Claims 5 and 9 are rejected under 35 U.S.C. § 103 as being unpatentable over Loetscher et al. or Schall et al.

20

The Examiner believes that all pertinent issues have been addressed.

15

20

THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 C.F.R. § 1.136(a).

A SHORTENED STATUTORY PERIOD FOR RESPONSE TO THIS FINAL

ACTION IS SET TO EXPIRE THREE MONTHS FROM THE DATE OF THIS
ACTION. IN THE EVENT A FIRST RESPONSE IS FILED WITHIN TWO MONTHS
OF THE MAILING DATE OF THIS FINAL ACTION AND THE ADVISORY ACTION
IS NOT MAILED UNTIL AFTER THE END OF THE THREE-MONTH SHORTENED
STATUTORY PERIOD, THEN THE SHORTENED STATUTORY PERIOD WILL EXPIRE
ON THE DATE THE ADVISORY ACTION IS MAILED, AND ANY EXTENSION FEE
PURSUANT TO 37 C.F.R. § 1.136(a) WILL BE CALCULATED FROM THE
MAILING DATE OF THE ADVISORY ACTION. IN NO EVENT WILL THE
STATUTORY PERIOD FOR RESPONSE EXPIRE LATER THAN SIX MONTHS FROM
THE DATE OF THIS FINAL ACTION.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Karen Cochrane Carlson, Ph.D. whose telephone number is (703) 308-0034.

Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist whose telephone number is (703) 308-0196.

ROBERT J. HILL, JR.
SUPERVISORY PATENT EXAMINER
GROUP 1800